β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes
QRS, fasting C-peptide, and CPest could be used as more efficient, less burdensome primary outcome measures for future immunotherapy trials. The ability of the Beta2 score to predict treatment responses could facilitate adaptive trial designs and help guide treatment decisions in the clinic.
Authors
- Thomas W. H. Kay (ORCID: https://orcid.org/0000-0002-7273-2556)
- Sara Vogrin (ORCID: https://orcid.org/0000-0002-1597-9421)
- John M. Wentworth (ORCID: https://orcid.org/0000-0002-5197-3529)
- Michelle So (ORCID: https://orcid.org/0000-0001-5411-3711)
- Michaela Waibel
Institutions
- The Royal Melbourne Hospital (AU)
- St Vincent's Hospital Melbourne (AU)
- St Vincents Institute of Medical Research (AU)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-05-27
- DOI
- https://doi.org/10.2337/dc25-0565
- Citations
- 1
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Leona M. and Harry B. Helmsley Charitable Trust
- Australian Government
- Juvenile Diabetes Research Foundation Australia
- National Center for Research Resources
- Division of Diabetes, Endocrinology, and Metabolic Diseases